Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!

Recent news

News archive

An Australian study published in the journal Supportive Care in Cancer has revealed that levels of physical activity decline after patients are diagnosed with myeloma.

The research surveyed 229 myeloma patients and found that participation in physical activity declined significantly from pre-diagnosis levels. Fatigue, injuries and pain were identified as the strongest perceived barriers to taking part. However, 41% of patients were willing to try an exercise programme if one was offered to them. Continue reading

The latest results from an international Phase III clinical study, show that pomalidomide with low-dose dexamethasone improves the length of remission and extends overall survival in relapsed and refractory myeloma patients.

Pomalidomide, an immunomodulatory drug (IMiD) similar to Revlimid® and derived from thalidomide, is being developed by the pharmaceutical company Celgene as a potential treatment in myeloma. Continue reading

MPE has welcomed the news today that the European Commission has approved a marketing licence for Velcade to be used as a subcutaneous (under the skin) injection for myeloma patients.

Velcade was the first in a class of anti-cancer drugs called proteasome inhibitors to be used in myeloma. It was first licensed in Europe in an IV formulation and since then Velcade has had a significant impact on the treatment of myeloma. Continue reading